Eleonora A. Markova

Eleonora A. Markova

Auto-generated profile, based on publicly available information

Eleonora A. Markova

Pirogov Russian National Research Medical University

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2016 in Lasers in Medical Science
Verified
Journal Article
Closed access
PDF file
VZV. V. Zverev
V. V. Zverev
OMO. V. Makarov
O. V. Makarov
AKA. Z. Khashukoeva
A. Z. Khashukoeva
OSOksana Svitich
Oksana Svitich
YDY. E. Dobrokhotova
Y. E. Dobrokhotova
LGL. V. Gankovskaya
L. V. Gankovskaya

9 October 2022 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
AKA. Z. Khashukoeva
A. Z. Khashukoeva
TDT. Y. Dmitrashko
T. Y. Dmitrashko
LNL. A. Nosova
L. A. Nosova
EME. A. Markova
E. A. Markova
AOA. V. Overko
A. V. Overko
As a result of the age-related decline in reproductive function, during the perimenopausal and postmenopausal periods female patients experience an estrogen deficiency state. Due to this state, symptoms of estrogen deficiency, which are combined into the concept of “climacteric syndrome”, begin to manifest. Climacteric syndrome is a complex of vegetative-vascular, mental, and metabolic-endocrine disorders that develop in women not only due to decrease in estrogen synthesis, but also the general ageing of the body. Clinical manifestations of the climacteric syndrome have a certain priority of development. With a decrease of the hormonal function of the ovaries, vasomotor disorders step forward. They represent all forms of autonomic regulation disorders, such as hot flashes, arterial pressure and pulse liability, respiratory disorders, hyperhydrosis, chills, and many others. In this article, the greatest emphasis is placed on the issue of vasomotor disorders, in particular hot flashes, in women of the perimenopausal and postmenopausal periods. Attention is paid to the medical and social component of the issue discussed. Given the fact that today the life expectancy of people, including women, is significantly increasing in the developed countries, a large number of females are faced with the issue of menopausal syndrome. The clinical manifestations of menopause not only have an extremely negative impact on the women’s quality of life, but also lay the groundwork for the development of more severe somatic disorders. The article also considers in detail the frequency of hot flashes, and the pathogenetic mechanisms of their development. The “gold standard” for the treatment of patients suffering from vasomotor disorders is particularly detailed. Today, the menopausal hormone therapy is recognized as the most effective therapeutic approach, which, subject to a personalized approach to patients and the absence of contraindications to its prescription, demonstrates high protective capabilities.

19 April 2023 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
OSO. A. Slyusareva
O. A. Slyusareva
AMA. E. Markarov
A. E. Markarov
SAS. V. Apresyan
S. V. Apresyan
JDJ. E. Dobrokhotova
J. E. Dobrokhotova
SKS. A. Khlynova
S. A. Khlynova
EME. A. Markova
E. A. Markova
Introduction. The efficacy of preoperative therapy with Gynestril in the treatment of symptomatic uterine fibroids and anaemia of various degrees of severity was studied in the prospective, comparative cohort study.Aim. To evaluate the efficacy of preoperative therapy with mifepristone in patients with uterine fibroids and chronic iron deficiency anaemia of various degrees of severity.Materials and methods. The study included 70 women who were scheduled to undergo the organ-preserving surgical treatment due to symptomatic uterine fibroids from January 1, 2017 to December 31, 2022. 50 patients received Gynestril at a dose of 50 mg/day (1 tablet) from day 1 of the menstrual cycle for 3 consecutive months. Due to contraindications to its use, 20 patients refused to administer the drug in the preoperative period and received symptomatic haemostatic therapy, and were included in the control groups. The patients of both groups received anti-anaemic therapy with iron(III)-hydroxide polymaltose tablets, 250– 300 mg/ day orally. 40 patients underwent the organ-preserving surgery depending on the size, number, type and localization of uterine fibroids according to the FIGO 2011 classification and patients’ motivation to preserve their reproductive function.Results. The analysis of changes in the laboratory test results revealed that hemoglobin levels in the groups after Gynestril therapy reached reference ranges in all women, averaging 123.4 ± 8.2 g/l as compared to the baseline value 84.3 ± 6.7 g/l, p < 0.05. It was also noted that ferritin levels increased significantly, averaging 12.2 ± 1.9 µg/l compared to the pre-treatment level 8.8 ± 0.8 µg/l, serum iron levels reached 12.8 ± 1.0 compared to the pre-treatment level 8.0 ± 0.8, and TIBC level reduced to 72.1 ± 3.5 compared to the pre-treatment level 96.7 ± 4.8 (p < 0.05).Conclusions. A comprehensive multidisciplinary approach to the treatment of uterine fibroids, including preoperative therapy with Gynestril, myomectomy using occlusive and X-ray endovascular techniques preserved the reproductive function in 50 patients with symptomatic uterine fibroids and anaemia of various degrees of severity.

1 January 2020 in Russian Journal of Woman and Child Health
Verified
Journal Article
Open access
YDYu.E Dobrokhotova
Yu.E Dobrokhotova
EME.A. Markova
E.A. Markova
Iron-deficiency anemia (IDA) is an important issue. The prevalence of IDA in women of reproductive age and women in perimenopause is high and has no tendency to reduce. Pharmacoeconomic aspects and recent data on clinical efficacy of iron supplements for obstetrical gy-necological disorders are addressed. The authors review international and domestic published data on iron supplements prescribed in women with obstetrical gynecological diseases. The paper describes the results of cost-effectiveness analysis and clinical trials published earlier that compare the efficacy of the treatment with iron supplements in women who experienced IDA or gynecological disorders complicated by iron deficiency during the pregnancy. One of the bivalent iron retard preparations, Tardyferon®, is discussed. In addition, Tardyferon® is compared with similar iron supplements and Fe(III)-hydroxide-polymaltose complex. Pharmacoeconomic utility of bivalent iron preparation from the viewpoint of the patient and the doctor is validated.Keywords: pharmacoeconomic analysis, iron deficiency, iron-deficiency anemia, pregnancy, iron supplements, bivalent iron.For citation: Dobrokhotova Yu.E., Markova E.A. Peroral retard iron preparation for iron-deficiency anemia: case study and pharmacoecono-mic analysis. Russian Journal of Woman and Child Health. 2020;3(2):88–94. DOI: 10.32364/2618-8430-2020-3-2-88-94.

21 July 2020 in Akusherstvo i ginekologiia
Verified
Journal Article
Closed access
KKKhashukoeva A.Z. Khashukoeva
Khashukoeva A.Z. Khashukoeva
DDDobrokhotova Yu.E. Dobrokhotova
Dobrokhotova Yu.E. Dobrokhotova
KKKhlynova S.A. Khlynova
Khlynova S.A. Khlynova
MEMarkova E.A. Markova E
Markova E.A. Markova E
SSSukhova T.N. Sukhova
Sukhova T.N. Sukhova
MMMyasoutova A.I. Myasoutova
Myasoutova A.I. Myasoutova

1 January 2022 in Russian Journal of Human Reproduction
Verified
Journal Article
Closed access
JDJ.E. Dobrokhotova
J.E. Dobrokhotova
EME.A. Markova
E.A. Markova
ЦЕЛЬ ИССЛЕДОВАНИЯ Изучение и анализ источников литературы по распространенности, этиологии и методам лечения смешанного вагинита. МАТЕРИАЛ И МЕТОДЫ Выполнен обзор данных литературы за последние 10 лет о распространенности смешанного вагинита, этиологических факторах и проблемах лечения. РЕЗУЛЬТАТЫ Получены актуальные данные о высокой распространенности смешанного вагинита, особенностях течения смешанной инфекции, формировании резистентности к лечению. Сделан вывод о необходимости пересмотра подходов к диагностике и лечению смешанного вагинита. ЗАКЛЮЧЕНИЕ В настоящее время при лечении пациенток со смешанным вагинитом предпочтение отдается местным комбинированным препаратам широкого спектра действия для эффективной элиминации патогенов, профилактики формирования рецидивов и создания условий по восстановлению собственной микрофлоры. Рациональным выбором может считаться препарат Полижинакс, включающий 3 компонента против наиболее частых возбудителей вагинитов: два антибиотика — неомицин и полимиксин В и антимикотик — нистатин.